Oğuz Evlice, Murat Bektaş, Fatih Kar, Feride Marim, İlknur Kaya, Kerem Yörükoğlu, Öznur Ak
{"title":"COVID-19 住院患者血清 Krebs von den Lungen-6 (KL-6) 水平与疾病严重程度的关系。","authors":"Oğuz Evlice, Murat Bektaş, Fatih Kar, Feride Marim, İlknur Kaya, Kerem Yörükoğlu, Öznur Ak","doi":"10.36519/idcm.2023.260","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>We aimed to evaluate Krebs von den Lungen-6 (KL-6) as a possible biomarker in determining disease severity in patients with moderate and severe COVID-19.</p><p><strong>Materials and methods: </strong>This cross-sectional study included moderate or severe COVID-19 patients; critically ill patients who were followed up in the intensive care unit were not included. KL-6 level and routine laboratory test measurements were performed on the first day of admission. The patients were also categorized according to their hyperinflammatory state.</p><p><strong>Results: </strong>The study included 92 patients, 56 (61%) women. The National Institutes of Health (NIH) score was 2 in 52.2% of the patients and 3 in 47.8%. KL-6 levels did not significantly differ in disease severity (NIH score 2 vs. 3; <i>p</i>=0.15). Median KL-6 values were 52.7 (29.1) in patients with <2 COVID-19 hyperinflammatory syndrome score (cHIS) and 61.7 (32.2) in patients with cHIS ≥ 2 (<i>p</i>= 0.077). KL-6 values tended to be higher among the patients with lower lymphocyte counts, but the difference was not statistically significant (<1000 mm³/L <i>p</i>=0.006 and higher cHIS scores ≥2 <i>p</i>=0.07). KL-6 values were also higher in the patients with diabetes mellitus compared to the remaining patients (<i>p</i> =0.036).</p><p><strong>Conclusion: </strong>There was no significant association between the serum KL-6 measured at admission and the severity of COVID-19.</p>","PeriodicalId":519881,"journal":{"name":"Infectious diseases & clinical microbiology","volume":"5 4","pages":"292-299"},"PeriodicalIF":0.0000,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10986708/pdf/","citationCount":"0","resultStr":"{\"title\":\"Association of Serum Krebs von den Lungen-6 (KL-6) Levels and Disease Severity in Patients Hospitalized with COVID-19.\",\"authors\":\"Oğuz Evlice, Murat Bektaş, Fatih Kar, Feride Marim, İlknur Kaya, Kerem Yörükoğlu, Öznur Ak\",\"doi\":\"10.36519/idcm.2023.260\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>We aimed to evaluate Krebs von den Lungen-6 (KL-6) as a possible biomarker in determining disease severity in patients with moderate and severe COVID-19.</p><p><strong>Materials and methods: </strong>This cross-sectional study included moderate or severe COVID-19 patients; critically ill patients who were followed up in the intensive care unit were not included. KL-6 level and routine laboratory test measurements were performed on the first day of admission. The patients were also categorized according to their hyperinflammatory state.</p><p><strong>Results: </strong>The study included 92 patients, 56 (61%) women. The National Institutes of Health (NIH) score was 2 in 52.2% of the patients and 3 in 47.8%. KL-6 levels did not significantly differ in disease severity (NIH score 2 vs. 3; <i>p</i>=0.15). Median KL-6 values were 52.7 (29.1) in patients with <2 COVID-19 hyperinflammatory syndrome score (cHIS) and 61.7 (32.2) in patients with cHIS ≥ 2 (<i>p</i>= 0.077). KL-6 values tended to be higher among the patients with lower lymphocyte counts, but the difference was not statistically significant (<1000 mm³/L <i>p</i>=0.006 and higher cHIS scores ≥2 <i>p</i>=0.07). KL-6 values were also higher in the patients with diabetes mellitus compared to the remaining patients (<i>p</i> =0.036).</p><p><strong>Conclusion: </strong>There was no significant association between the serum KL-6 measured at admission and the severity of COVID-19.</p>\",\"PeriodicalId\":519881,\"journal\":{\"name\":\"Infectious diseases & clinical microbiology\",\"volume\":\"5 4\",\"pages\":\"292-299\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-12-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10986708/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Infectious diseases & clinical microbiology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.36519/idcm.2023.260\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/12/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious diseases & clinical microbiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36519/idcm.2023.260","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
Association of Serum Krebs von den Lungen-6 (KL-6) Levels and Disease Severity in Patients Hospitalized with COVID-19.
Objective: We aimed to evaluate Krebs von den Lungen-6 (KL-6) as a possible biomarker in determining disease severity in patients with moderate and severe COVID-19.
Materials and methods: This cross-sectional study included moderate or severe COVID-19 patients; critically ill patients who were followed up in the intensive care unit were not included. KL-6 level and routine laboratory test measurements were performed on the first day of admission. The patients were also categorized according to their hyperinflammatory state.
Results: The study included 92 patients, 56 (61%) women. The National Institutes of Health (NIH) score was 2 in 52.2% of the patients and 3 in 47.8%. KL-6 levels did not significantly differ in disease severity (NIH score 2 vs. 3; p=0.15). Median KL-6 values were 52.7 (29.1) in patients with <2 COVID-19 hyperinflammatory syndrome score (cHIS) and 61.7 (32.2) in patients with cHIS ≥ 2 (p= 0.077). KL-6 values tended to be higher among the patients with lower lymphocyte counts, but the difference was not statistically significant (<1000 mm³/L p=0.006 and higher cHIS scores ≥2 p=0.07). KL-6 values were also higher in the patients with diabetes mellitus compared to the remaining patients (p =0.036).
Conclusion: There was no significant association between the serum KL-6 measured at admission and the severity of COVID-19.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
